Financials
- Fiscal year
- 2024
- Turnover
- €1.4m
- Profit
- €79,630
- Solvency
- 63.1%
Turnover▲ 5.3%
Net result
20212024
NORDPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of NORDPHARMA is 2.9% (moderate). The 2024 annual accounts show equity of €494,640 and a net result of €79,630. Equity is growing by ~6.1% per year across the filed fiscal years. Its solvency ranks better than 80% of 6550 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.4mturnover 2024
- Staff
- 2.8 FTE
- Equity
- €494,640
- Profit
- €79,630
Structure
Accounts 67 d overdue0 of 2 deeds read
Why 52- 1 financial year not filed after the legal deadline; latest accounts 93 days late; 3 of the last 3 late- Figures for FY 2024 (filed 04-11-2025)- Founded in 2020+ Equity €494,640 (63.1% of total assets)Show the evidence
Checked score
Score 2024
52
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Better than 61% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2023
Strong
Solvency
88+1
equity 63.1% of total assets
Liquidity
51+1
short-term debt 34.3% · cash 13.3%
Profitability
74-2
return on assets 10.2%
Bankruptcy probability, 12 months
2.9%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 4.1%
12-2024: 4.9%▲ +18.8% vs 11-2024
01-2025: 7.0%▲ +43.5% vs 12-2024highest value
02-2025: 1.5%▼ -78.0% vs 01-2025
03-2025: 1.5%▼ -1.4% vs 02-2025
04-2025: 1.5%▲ +1.2% vs 03-2025
05-2025: 1.5%● 0.0% vs 04-2025
06-2025: 1.7%▲ +11.6% vs 05-2025
07-2025: 1.8%▲ +4.2% vs 06-2025
08-2025: 2.3%▲ +25.9% vs 07-2025
09-2025: 2.4%▲ +5.6% vs 08-2025
10-2025: 3.3%▲ +37.9% vs 09-2025
11-2025: 3.4%▲ +3.5% vs 10-2025
12-2025: 1.2%▼ -64.3% vs 11-2025
01-2026: 1.2%● 0.0% vs 12-2025
02-2026: 1.2%▲ +1.1% vs 01-2026
03-2026: 1.2%▼ -2.2% vs 02-2026
04-2026: 1.2%▼ -0.9% vs 03-2026
05-2026: 1.2%▼ -1.0% vs 04-2026lowest value
06-2026: 1.3%▲ +12.8% vs 05-2026
07-2026: 1.5%▲ +13.7% vs 06-2026
08-2026: 1.9%▲ +28.6% vs 07-2026
09-2026: 2.1%▲ +8.5% vs 08-2026
10-2026: 2.9%▲ +38.1% vs 09-2026
- 1 financial year not filed after the legal deadline; latest accounts 93 days late; 3 of the last 3 late raises the probability
- Figures for FY 2024 (filed 04-11-2025) raises the probability
- Equity €494,640 (63.1% of total assets) lowers the probability
- Founded in 2020 raises the probability for this profile
Credit up to €25,000 at 30 days only on tighter terms
Liquidity tight (current ratio 1.16 against 1.21 in 2023; short-term debt: 34.3% and cash: 13.3% of total assets), and 36.9% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 75%, liquidity 56%, profitability 58%, growth against the median 56%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 05-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk
raises risk · Filed more than 90 days late
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 01-11-2025, 93 days past the deadline. Measured on financial year 2023: companies more than 90 days late are in an abnormal legal state today in 5.61% of cases, against 1.66% across all filers.
NBB · 4 filingsDeviation from the deadline
2025
not confirmed
2024
93 d late
2023
149 d late
2022
167 d late
2021
532 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average 235 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (1)
- Annual accounts filedfiscal year 2024 · full…
- Highest result since 2021net €79,630 ▲2.6%
- Annual accounts filedfiscal year 2023 · full…
Key points
By topic
Timeline
- Events
- 6
- Since
- 2022
- 01-11-2025Annual accounts filed
- 31-12-2024Highest result since 2021
- 27-12-2024Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 07-07-2020
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.